M161 M161 (Didanosine Delayed Release 250 mg)

Pill with imprint M161 M161 is Yellow, Capsule-shape and has been identified as Didanosine Delayed Release 250 mg. It is supplied by Mylan Pharmaceuticals Inc..

Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for M161 M161

Didanosine Delayed Release

Imprint:

M161 M161

Strength:

250 mg

Color:

Yellow

Shape:

Capsule-shape

Availability:

Prescription only

Drug Class:

Nucleoside reverse transcriptase inhibitors (NRTIs)

Pregnancy Category:

B - No proven risk in humans

CSA Schedule:

Not a controlled drug

Labeler / Supplier:

Mylan Pharmaceuticals Inc.

Inactive Ingredients:

ferrosoferric oxide
carboxymethylcellulose sodium
silicon dioxide
diethyl phthalate
gelatin
hypromelloses
methacrylic acid - methyl methacrylate copolymer (1:1)
propylene glycol
ferric oxide red
shellac
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
magnesium silicate
titanium dioxide
ferric oxide yellow
potassium hydroxide
Note: Inactive ingredients may vary.

More Info Imprint SearchPrint

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer